Clinical Trials Logo
  1. Home
  2. Shingles
  3. NCT01262300

Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents

Shingles Clinical Trial

Official title:
Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Nursing Home Residents

Clinical Trial Summary

This is an ancillary study to a randomized controlled trial of high dose vitamin D in older long-term care residents (NCT01102374). In this study, a subset of trial subjects will receive the zoster vaccine and the investigators will determine the immunological response to the vaccine in this older, frail population, as well as the association between vitamin D and immunological outcomes.

Clinical Trial Description

Objectives 1. To determine the increase in Varicella-zoster virus (VZV)-specific cell-mediated immune response from pre-zoster vaccination to 3 weeks post-vaccination in nursing home residents after 4 months of high dose vs. standard dose vitamin D3 supplementation. 2. In the same participants as Aim 1, to measure the association between pre-zoster vaccination 25-hydroxyvitamin D [25(OH)D] levels and the increase in VZV-specific cell-mediated immune response from pre- vaccination to 3 weeks post-vaccination. 3. Characterize the phenotypic and functional VZV-specific T cell responses to Zostavax, including memory, effector, Th1/Th2, and homing receptor-bearing T cells in the high compared to low ELISPOT responders. Hypotheses 1. At baseline, higher serum 25(OH)D levels will be associated with higher levels of VZV-specific cell-mediated immunity (cross-sectional). 2. At baseline, higher serum 25(OH)D levels, independent of vitamin D supplementation dose, will be associated with greater increases in VZV-specific cell-mediated immune responses to Zostavax, as measured by the interferon (IFN)-γ ELISPOT assay. 3. Compared to standard dose, high dose vitamin D3 supplementation will enhance VZV-specific cell-mediated immune response to vaccination independent of baseline serum 25(OH)D levels. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01262300
Study type Interventional
Source University of Colorado, Denver
Contact
Status Completed
Phase Phase 1
Start date November 2010
Completion date January 23, 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT01132716 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions N/A
Completed NCT01132729 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions N/A
Completed NCT04099706 - Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT N/A
Completed NCT04540081 - Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer N/A
Completed NCT01527370 - Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025) Phase 3
Completed NCT00534248 - Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022) Phase 3
Completed NCT00576108 - A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN) Phase 2
Completed NCT00109122 - Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007) Phase 2
Completed NCT04047979 - Systems Biology of Zoster Vaccine Phase 2
Active, not recruiting NCT05871541 - A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine Phase 1
Completed NCT02114333 - Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds Phase 1
Completed NCT00900783 - A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster Phase 2
Completed NCT01600079 - ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
Active, not recruiting NCT02444936 - ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors Phase 4
Recruiting NCT05554068 - Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Phase 2
Recruiting NCT06238726 - Nudging Patients to Increase Shingles Vaccination N/A
Completed NCT02704572 - Optimal Timing of Zoster Vaccine After Zoster Illness N/A
Completed NCT00300222 - Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Phase 3
Terminated NCT02412917 - A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia Phase 3
Completed NCT00115310 - Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Phase 3